MGRX - high-volatility-and-mixed-signals-cloud-companys-outlook

Deep-Dive Due Diligence AI Generated Report on Mangoceuticals, Inc. Common Stock (MGRX)

Welcome to ScanScor. What you're reading is not just a stock summary -- it's a real-time, AI-generated due diligence session crafted from live news, financial data, insider trading activity, SEC filings, and live market momentum.

These reports are generated using OpenAI's GPT-based analysis engine, guided by tightly structured prompts and expert-level data ingestion. Every insight below was assembled to help you understand the forces behind today's market movers.

Disclaimer: This report is for informational purposes only. It does not constitute financial advice. Always do your own research before making any investment.

MGRX_OUT_1 [2025-03-19 15:31:23 -0400] 2555 Bytes | 675 tokens | Cum: 675 tkns (8.44% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at Mangoceuticals (MGRX) which is at 4.5008 up from 3.62. So, I pulled together a bunch of data for you to look over real fast. It's still early, 03:31:22 PM on Wednesday March 19, 2025 ET (UTC-0400). So, what's the verdict? You're the expert!

Here's the first list of news for Mangoceuticals:

C1 - Feb-20-25 07:00AM - Mangoceuticals Announces the Launch of PeachesRx - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments
C2 - Feb-12-25 08:00AM - Mangoceuticals Advances Antiviral Research on its Patented Respiratory Illness Prevention Technology With New Study Targeting Avian Flu in Poultry Using a Non-Invasive, Non-Pharmaceutical Water-Based Solution
C3 - Feb-06-25 07:00AM - Mangoceuticals Advances H1N1 Efficacy Study Noting Significant Reduction in Viral Load in Phase 1 Studies and Engages Vipragen Biosciences to Structure H5N1 Cohort for Expanded Research
C4 - Feb-03-25 08:30AM - Mangoceuticals, Inc. Executes Exclusive Distribution Agreement with Propre Energie for Clinically Proven Dermytol Skincare Treatment Targeting Hyperpigmentation
C5 - Dec-19-24 05:33PM - Mangoceuticals, Inc. Completes Acquisition of Mushroom-Based Wellness and Innovations Patent
C6 - Dec-04-24 07:00AM - Mangoceuticals, Inc. Initiates Investigation into Potential Stock Manipulation Scheme Following Recent Reverse Stock Split
C7 - Oct-31-24 08:00AM - Mangoceuticals, Inc. Regains Full Compliance with Nasdaq Minimum Bid Price Requirement
C8 - Oct-22-24 08:00AM - MangoRx Announces Formation of Strategy and Alternatives Committee

ONLY 3 RULES for AI:
==============
1) This is a document retrieval system. You are the analyst-investigator.
2) You can request items from any list to get more details about Mangoceuticals (MGRX)
3) AFTER requesting and reading News and SEC filings you'll get tokens to write a summary, set a score and high price target, and finally take an exit quiz.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.

Thank you for your analysis of Mangoceuticals.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!

Please request a document, read, summarize and score. Say something like "C1".

MGRX_IN_2 [2025-03-19 15:31:23 -0400] 2 Bytes | 2 tokens | Cum: 677 tkns (8.46% of 8k)
==========================================================================

MGRX_OUT_3 [2025-03-19 15:31:28 -0400] 972 Bytes | 295 tokens | Cum: 972 tkns (12.15% of 8k)
==========================================================================

Showing C1 (chunk 1 of 19): C1:
**Mangoceuticals Announces the Launch of PeachesRx - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments**
Date: Feb-20-25 07:00AM
Source: (GlobeNewswire)
URL: https://www.globenewswire.com/news-release/2025/02/20/3029474/0/en/Mangoceuticals-Announces-the-Launch-of-PeachesRx-a-Women-s-Telehealth-Brand-Focused-on-Personalized-Wellness-and-GLP-1-Weight-Loss-Treatments.html

February 20, 2025 07:00 ET| Source:Mangoceuticals, Inc.Mangoceuticals, Inc.

Dallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) --Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men’s wellness products via a secure telemedicine platform under the brand MangoRx, proudly announces the official launch of PeachesRx, an innovative women’s health and wellness brand focused on providing cuttin

-- More? (MOR) or Next section? (NEX)

MGRX_IN_4 [2025-03-19 15:31:28 -0400] 12 Bytes | 2 tokens | Cum: 974 tkns (12.17% of 8k)
==========================================================================

Next section

MGRX_OUT_5 [2025-03-19 15:31:30 -0400] 643 Bytes | 178 tokens | Cum: 1152 tkns (14.40% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-02-20T12:03:29Z - Mangoceuticals Announces the Launch of "PeachesRx" - a Women's Telehealth Brand Focused on Personali...
A2 - 2025-02-20T12:38:25Z - Mangoceuticals Announces the Launch of 'PeachesRx" - a Women's Telehealth Brand Focused on Personali...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

MGRX_IN_6 [2025-03-19 15:31:30 -0400] 2 Bytes | 2 tokens | Cum: 1154 tkns (14.42% of 8k)
==========================================================================

MGRX_OUT_7 [2025-03-19 15:31:31 -0400] 967 Bytes | 265 tokens | Cum: 1419 tkns (17.74% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**Mangoceuticals Announces the Launch of "PeachesRx" - a Women's Telehealth Brand Focused on Personalized Wellness and GLP-1 Weight Loss Treatments**Date: 2025-02-20Source: {'uri': 'wallstreet-online.de', 'dataType': 'news', 'title': 'wallstreet:online'}URL: https://www.wallstreet-online.de/nachricht/19024673-mangoceuticals-announces-the-launch-of-peachesrx-a-women-s-telehealth-brand-focused-on-personalized-wellness-and-glp-1-weight-loss-treatmentsDallas, Texas, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Mangoceuticals, Inc. (NASDAQ: MGRX) ("Mangoceuticals" or the "Company"), a company focused on developing, marketing, and selling a variety of men's wellness products via a secure telemedicine platform under the brand MangoRx, proudly announces the official launch of PeachesRx, an innovative women's health and wellness brand focused on providing cutting-edge, convenient treatments tailored to

-- More? (MOR) or Next section? (NEX)

MGRX_IN_8 [2025-03-19 15:31:31 -0400] 3 Bytes | 2 tokens | Cum: 1421 tkns (17.76% of 8k)
==========================================================================

MOR

MGRX_OUT_9 [2025-03-19 15:31:41 -0400] 793 Bytes | 166 tokens | Cum: 1587 tkns (19.84% of 8k)
==========================================================================

Showing A1 (chunk 2 of 2): women's unique health needs. These new and innovative women's health and wellness products will be made available via a secure telemedicine platform located at www.PeachesRx.com.

PeachesRx will debut with a strong focus on compounded GLP-1 receptor agonists -- a class of medications proven to aid weight loss by regulating appetite and glucose metabolism. Recent studies show that approximately 70% of GLP-1 prescriptions for weight loss are written for women, reflecting their dominant role in driving the surge in demand for these medications. By introducing its tailored GLP-1 offerings, PeachesRx aims to meet the unique metabolic needs of women while providing an accessible and affordable telehealth-driven solution.

-- More? (MOR) or Next section? (NEX)

MGRX_IN_10 [2025-03-19 15:31:41 -0400] 1136 Bytes | 204 tokens | Cum: 1791 tkns (22.39% of 8k)
==========================================================================

As a financial analyst, I would be interested in the potential economic impact of this new venture. I would look into the market size for women's health and wellness products, especially in the area of weight loss medications. I would also investigate the financials of the company introducing these products, including their capital, their predicted revenue from these new products, and their marketing strategy.

The increasing demand for GLP-1 prescriptions for weight loss indicates a growing market, which could mean significant profits for the company if they can effectively meet this demand. However, the costs of developing and producing these tailored GLP-1 offerings should also be considered.

Additionally, the use of a telehealth platform could potentially reduce the company's overhead costs and allow them to reach a larger customer base. However, it would also require investment in technology and potentially face competition from other online health platforms.

In conclusion, while there is potential for significant financial gain, there are also a number of costs and risks which need to be carefully evaluated.

MGRX_OUT_11 [2025-03-19 15:31:42 -0400] 1090 Bytes | 311 tokens | Cum: 2102 tkns (26.27% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-07-12T18:11:34Z - Azz Inc. COO acquires $21.2k in company stock By Investing.com - Investing.com Australia
B2 - 2024-06-06T12:30:00Z - MangoRx Receives Notice of Acceptance for Patent Application in Australia for Respiratory Illness and Preventive Care Technology
B3 - 2024-06-04T20:00:00Z - MangoRx Receives Patent Notice of Allowance in Japan for Revolutionary Preventive Care Technology Acquired from Intramont Technologies
B4 - 2024-05-23T12:30:00Z - MangoRx Engages Renown International Digital and Performance Marketing Company Crakmedia to Champion its Digital Marketing Efforts
B5 - 2024-05-22T10:52:00Z - Spotting Penny Stocks Before They Explode, Top Tips
B6 - 2024-05-16T20:40:00Z - MangoRx Reports Revenue Growth of 108% in Q1 2024 Fueled by Amplified Customer Acquisition and Early Market Penetration

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

MGRX_IN_12 [2025-03-19 15:31:42 -0400] 2 Bytes | 2 tokens | Cum: 2104 tkns (26.30% of 8k)
==========================================================================

MGRX_OUT_13 [2025-03-19 15:31:50 -0400] 640 Bytes | 155 tokens | Cum: 2259 tkns (28.24% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**Azz Inc. COO acquires $21.2k in company stock By Investing.com - Investing.com Australia**Date: Unknown DateSource: Unknown SourceURL: https://au.investing.com/news/company-news/mangoceuticals-appoints-new-research-director-93CH-3339028Mangoceuticals, a health and wellness company, has appointed Dr. Douglas Christianson as the new Director of Medical Research and Product Innovation. Dr. Christianson will lead the company's product development efforts, particularly in areas like erectile dysfunction, hair growth, weight loss, and hormone replacement therapies.

-- More? (MOR) or Next section? (NEX)

MGRX_IN_14 [2025-03-19 15:31:50 -0400] 989 Bytes | 189 tokens | Cum: 2448 tkns (30.60% of 8k)
==========================================================================

Your prompt seems to be a mix of two different news, one about Azz Inc. COO acquiring company stock and another about Mangoceuticals appointing a new director.

For Azz Inc., a significant stock acquisition by a company executive could indicate a strong belief in the company's future performance. As a financial analyst, you might want to look into this further, as it could be a sign of insider confidence.

For Mangoceuticals, the appointment of Dr. Douglas Christianson as the new Director of Medical Research and Product Innovation may have implications for the company's future growth. If Dr. Christianson's efforts in product development are successful, especially in the mentioned areas of erectile dysfunction, hair growth, weight loss, and hormone replacement therapies, this could potentially benefit the company's financial performance in the long term. However, it is essential to assess the risks associated with the development and marketing of new products in these areas.

MGRX_OUT_15 [2025-03-19 15:31:52 -0400] 1143 Bytes | 321 tokens | Cum: 2769 tkns (34.61% of 8k)
==========================================================================

This is our list of SEC filings.
Read it just by asking.
Don't miss breaking filings!

S1 - 2025-03-19 8-K Item 9.01 Fin Stmnts and Exhibits.

(d) Exhibits.

Exhibit

No.

S2 - 2025-02-19 8-K Item 1.01. Entry into a Material Definitive Agrmt.

Consulting Agrmt

On February 19, 2025, Mangoceuticals, Inc. (the Company , we and us ) entered into a Consulting Agrmt with 6330 Investment Consulting Gmbh ( 6330 Consulting ), to provide certain strategic busines...

S3 - 2025-02-12 8-K Item 1.01. Entry into a Material Definitive Agrmt.

Letter Agrmt Relating to Patent Purchase Agrmt

As previously disclosed in the Curr Report on Form 8-K filed by Mangoceuticals, Inc. (the Company , we and us ) with the Securities and Exchange Commission on Apri...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing - but what fun is that?
Response limited to 3 chars.

MGRX_IN_16 [2025-03-19 15:31:52 -0400] 2 Bytes | 2 tokens | Cum: 2771 tkns (34.64% of 8k)
==========================================================================

MGRX_OUT_17 [2025-03-19 15:31:54 -0400] 967 Bytes | 259 tokens | Cum: 3030 tkns (37.88% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

Exhibit

No.

Description 3.1 Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., filed with the Secretary of State of Texas on March 28, 2024 (Filed as Exhibit 3.3 to the Companys Annual Report on Form 10-K, filed with the SEC on April 1, 2024, and incorporated by reference herein) 3.2 Amendment to Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., submitted to the Secretary of State of Texas on June 27, 2024 (Filed as Exhibit 3.2 to the Companys Quarterly Report on Form 10-8, filed with the SEC on July 2, 2, 2024, and incorporated by reference herein) 3.3* Amendment to Certificate of Designations, Preferences and Rights of Series B Convertible Preferred Stock of Mangoceuticals, Inc., subm

-- More? (MOR) or Next section? (NEX)

MGRX_IN_18 [2025-03-19 15:31:54 -0400] 3 Bytes | 2 tokens | Cum: 3032 tkns (37.90% of 8k)
==========================================================================

NEX

MGRX_OUT_19 [2025-03-19 15:32:05 -0400] 3144 Bytes | 768 tokens | Cum: 3800 tkns (47.50% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

The next section covers any insider trading.
If this section is blank, it's because there've been no recent filings.

No transactions recorded.

Now we've reached the end of the analysis.
You are now allotted tokens to make a final analysis summary.
Please don't use tokens to explain why you didn't have enough information.
Save that for the survey that comes last.

Finish the summary with two scores: MARKET_SCORE[] and PRICE_TARGET[]

If you think there's a 90% likelihood of an upward moves, say: MARKET_SCORE[90]
If you think the high today will be 50% higher, add to the price. Eg., If the price is $5.00, add 50%: PRICE_TARGET[$7.50]
PRICE_TARGET is the highest it is expected to rise today, so it cannot be less than the current price.

After you have completed that, please provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-10 words headline for news story from first summary paragraph]

MGRX_IN_20 [2025-03-19 15:32:05 -0400] 1441 Bytes | 319 tokens | Cum: 4119 tkns (51.49% of 8k)
==========================================================================

Based on the metrics provided, this company seems to be experiencing a high level of volatility. The company's stock price has increased by 24.31% from its previous close, indicating a strong upward trend. However, the company's performance over the past month has declined by -6.83%, suggesting some instability.

The Relative Strength Index (RSI) stands at 54.51, which is a neutral position, indicating that the stock is neither overbought nor oversold. The average true range (ATR) is 0.57, which shows the stock's volatility.

The company's Return on Equity (ROE) is significantly negative at -124.39%, indicating that the company is not generating a positive return for its investors. Similarly, the Return on Investment (ROI) is also negative at -68.31%, further indicating poor returns.

Moreover, the company's sales Q/Q have notably decreased by -45.60%, which could be a red flag for investors. Despite the negative sales Q/Q, the company has experienced significant sales growth over the past five years, with a growth rate of 4041.58%.

The company's debt to equity ratio is relatively low at 0.02, suggesting that the company is not heavily reliant on debt to finance its operations.

Given the mixed signals from these metrics, it's hard to predict the company's future performance without more information.

MARKET_SCORE[50]
PRICE_TARGET[$4.90]

AI_RPT_HEADLINE: "High Volatility and Mixed Signals Cloud Company's Outlook"

MGRX_OUT_21 [2025-03-19 15:32:07 -0400] 561 Bytes | 131 tokens | Cum: 4250 tkns (53.12% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings & insider data
-> X3 <- Broader sector & market news
-> X4 <- General market sentiment & AI confidence levels
-> X5 <- AI's past analysis on similar companies
-> X6 <- More financial metrics
-> X7 <- AI's past analysis on this exact company
-> X8 <- Something altogether different (explain...)

MGRX_IN_22 [2025-03-19 15:32:07 -0400] 40 Bytes | 10 tokens | Cum: 4260 tkns (53.25% of 8k)
==========================================================================

-> X2 <- More SEC filings & insider data

MGRX_IN_23 [2025-03-19 15:32:07 -0400] 126 Bytes | 29 tokens | Cum: 4289 tkns (53.61% of 8k)
==========================================================================

====================================
[2025-03-19 12:32:07] # Analysis Completed
Elapsed Time: 46.06 seconds